Peter Mudry Selected Research

Neutropenia

11/2019

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Mudry Research Topics

Disease

12	Neoplasms (Cancer) 01/2022 - 07/2006
7	Sarcoma (Soft Tissue Sarcoma) 01/2023 - 04/2016
4	Rhabdomyosarcoma 11/2019 - 01/2011
3	Osteosarcoma (Osteogenic Sarcoma) 07/2016 - 05/2012
2	Myofibromatosis 09/2018 - 10/2017
1	Vascular Malformations 01/2023
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2022
1	Residual Neoplasm 01/2022
1	Giant Cell Tumor of Bone 07/2021
1	Infections 11/2019
1	Thrombocytopenia (Thrombopenia) 11/2019
1	Neutropenia 11/2019
1	Pain (Aches) 11/2019
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2019
1	Neuroblastoma 01/2019
1	Nijmegen Breakage Syndrome 10/2017
1	Invasive Candidiasis 01/2017
1	Candidiasis (Moniliasis) 01/2017
1	Aspergillosis 01/2017
1	Ewing Sarcoma (Sarcoma, Ewing) 06/2016
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2010
1	Peritonitis 03/2010
1	Invasive Fungal Infections 03/2010

Drug/Important Bio-Agent (IBA)

4	NestinIBA 07/2016 - 01/2011
2	Proteins (Proteins, Gene)FDA Link 07/2021 - 01/2011
2	Sunitinib (Sutent)FDA Link 07/2021 - 09/2018
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2019
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2019 - 01/2019
2	VaccinesIBA 01/2019 - 01/2019
2	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 09/2018 - 10/2017
1	Dactinomycin (Actinomycin)FDA LinkGeneric 01/2023
1	AlpelisibIBA 01/2023
1	Vincristine (Oncovin)FDA LinkGeneric 01/2023
1	Ifosfamide FDA LinkGeneric 01/2023
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023
1	lorlatinibIBA 01/2022
1	Monoclonal AntibodiesIBA 07/2021
1	PhosphoproteinsIBA 07/2021
1	Denosumab FDA Link 07/2021
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Vasopressins (Vasopressin)IBA 11/2019
1	Vinorelbine (Navelbine)FDA LinkGeneric 11/2019
1	AutoantigensIBA 01/2019
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2019
1	AntigensIBA 01/2019
1	Temozolomide (Temodar)FDA LinkGeneric 01/2019
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2019
1	Cancer VaccinesIBA 01/2019
1	Topotecan (Hycamtin)FDA LinkGeneric 01/2019
1	pazopanib FDA Link 01/2019
1	Phosphotransferases (Kinase)IBA 09/2018
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2018
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 09/2018
1	Voriconazole (Vfend)FDA LinkGeneric 01/2017
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2011
1	Amphotericin B (Amphotericin)FDA LinkGeneric 03/2010
1	efungumabIBA 03/2010
1	Colloids (Colloid)IBA 03/2010

Therapy/Procedure

6	Therapeutics 01/2019 - 07/2006
3	Drug Therapy (Chemotherapy) 11/2019 - 10/2017
2	Maintenance Chemotherapy 01/2023 - 11/2019
2	Immunotherapy 01/2019 - 01/2019
1	Precision Medicine 07/2021
1	Induction Chemotherapy 03/2010